Stockcalc – Free Trial
Have a free look inside the StockCalc website at www.stockcalc.com
I have used the analysis tools on the website stockcalc.com to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com/TopPicks.aspx.
Undervalued Stocks on NASDAQ
Today we are looking at companies that are considered undervalued based on the Analyst data in the StockCalc database.
In the table below we can see the close price and target price for these companies along with the number of analysts covering the stock. We also have included the fiscal year for the target price as sometimes these analyst targets are not for the current or even the next fiscal year.
There can be a number of reasons why a company would be on this list. What is particularly interesting are companies with a large analyst following that make this list. We need to dig deeper into these companies to understand why the difference in price versus target.
Today’s Data on NASDAQ
Today’s data is for companies listed on the NASDAQ.
| Symbol | Name | Target Year | Close Price | Target Price Mean | Currency | Target Price # of Estimates |
|---|---|---|---|---|---|---|
| AMZN | Amazon.com Inc | 2018 | 1581.400000 | 1843.5450 | USD | 11 |
| GOOG | Alphabet Inc | 2018 | 1069.730000 | 1251.8180 | USD | 11 |
| GOOGL | Alphabet Inc | 2018 | 1075.310000 | 1251.8180 | USD | 11 |
| BKNG | Booking Holdings Inc | 2018 | 2077.190000 | 2338.3330 | USD | 6 |
| AVGO | Broadcom Inc | 2018 | 238.490000 | 321.5000 | USD | 10 |
| CHTR | Charter Communications Inc | 2018 | 267.660000 | 409.5000 | USD | 4 |
| BIIB | Biogen Inc | 2018 | 279.690000 | 340.8750 | USD | 8 |
| CELG | Celgene Corp | 2018 | 76.610000 | 127.0000 | USD | 7 |
| SHPG | Shire PLC | 2018 | 169.890000 | 217.9589 | USD | 4 |
| LRCX | Lam Research Corp | 2019 | 202.980000 | 268.2857 | USD | 7 |
| REGN | Regeneron Pharmaceuticals Inc | 2018 | 294.680000 | 393.6667 | USD | 6 |
| EQIX | Equinix Inc | 2018 | 383.190000 | 515.0000 | USD | 5 |
| MELI | MercadoLibre Inc | 2018 | 294.760000 | 380.0000 | USD | 1 |
| SINA | SINA Corp | 2018 | 90.390000 | 159.0000 | USD | 1 |
| COHR | Coherent Inc | 2018 | 170.500000 | 246.0000 | USD | 3 |
| TREE | LendingTree Inc | 2018 | 265.450000 | 324.8000 | USD | 5 |
| ICPT | Intercept Pharmaceuticals Inc | 2018 | 69.990000 | 125.0000 | USD | 4 |
| ANAB | AnaptysBio Inc | 2018 | 86.200000 | 135.0000 | USD | 1 |
| AMWD | American Woodmark Corp | 2019 | 85.300000 | 156.0000 | USD | 1 |
| OSTK | Overstock.com Inc | 2018 | 36.250000 | 100.0000 | USD | 1 |
| VRTS | Virtus Investment Partners Inc | 2018 | 126.350000 | 173.0000 | USD | 1 |
| ADMS | Adamas Pharmaceuticals Inc | 2018 | 29.740000 | 91.0000 | USD | 1 |
| ALBO | Albireo Pharma Inc | 2018 | 32.950000 | 86.0000 | USD | 1 |
| CHEK | Check-Cap Ltd | 2018 | 4.650000 | 72.0003 | USD | 1 |
| RTTR | Ritter Pharmaceuticals Inc | 2018 | 3.120000 | 81.0000 | USD | 2 |
Let’s look at a few companies…
Lets look at a couple of the companies on this list to get a better understanding of them.
CELG:NAS Celgene
http://www.celgene.com
Celgene has 7467 employees and is headquartered in United States.
Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.
LRCX:NAS Lam Research
http://www.lamrc.com
Lam Research has 9400 employees and is headquartered in United States.
Lam Research Corp functions in the semiconductor industry. It develops and sells semiconductor processing systems that are used in the fabrication of integrated circuits.
Free Valuation
Run a valuation on any of the companies listed above at www.stockcalc.com/valureport.aspx or subscribe at our Stockcalc Facebook Page to receive this list each day Stockcalc Reports.
The content presented here is in part from the website stockcalc.com and is provided on an as is or as available basis with all faults and may not be current in all cases. You should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment decision.